Association of circulating omentin level and metabolic-associated fatty liver disease: a systematic review and meta-analysis

Association of circulating omentin level and metabolic-associated fatty liver disease: a systematic review and meta-analysis

BackgroundMetabolic-associated fatty liver disease (MAFLD) is closely associated with omentin, a novel adipokine that plays a vital role in metabolic balance. The literature about the relationship between circulating omentin and MAFLD is conflicting. Therefore, this meta-analysis evaluated circulati...

Full description

Bibliographic Details
Main Authors:	Qin Zhang, Shuaihang Chen, Yani Ke, Qicong Li, Chenglu Shen, Yuting Ruan, Kaihan Wu, Jie Hu, Shan Liu
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-04-01
Series:	Frontiers in Endocrinology
Subjects:	metabolic-associated fatty liver disease (MAFLD) non-alcoholic fatty liver disease omentin systematic review meta-analysis
Online Access:	https://www.frontiersin.org/articles/10.3389/fendo.2023.1073498/full

Similar Items

Association of circulating vaspin levels and patients with metabolic-associated fatty liver disease: a systematic review and meta-analysis
by: Yuqing Zhu, et al.
Published: (2022-07-01)

Serum omentin-1, vaspin, and apelin levels and central obesity in patients with nonalcoholic fatty liver disease
by: Farzaneh Montazerifar, et al.
Published: (2017-01-01)

Autophagy Dysregulation in Metabolic Associated Fatty Liver Disease: A New Therapeutic Target
by: Chun-Liang Chen, et al.
Published: (2022-09-01)

The Evaluation of Drug Delivery Nanocarrier Development and Pharmacological Briefing for Metabolic-Associated Fatty Liver Disease (MAFLD): An Update
by: Reem Abou Assi, et al.
Published: (2021-03-01)

Historical narrative from fatty liver in the nineteenth century to contemporary NAFLD – Reconciling the present with the pastKey points
by: Oyekoya T. Ayonrinde
Published: (2021-06-01)

Circulating angiopoietin-like proteins in metabolic-associated fatty liver disease: a systematic review and meta-analysis
by: Yani Ke, et al.
Published: (2021-05-01)

Precision Medicine in Fatty Liver Disease/Non-Alcoholic Fatty Liver Disease
by: Laura Valenzuela-Vallejo, et al.
Published: (2023-05-01)

Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention
by: Xiao-Dong Zhou, et al.
Published: (2022-12-01)

What’s Past Is Prologue: History of Nonalcoholic Fatty Liver Disease
by: Giovanni Targher
Published: (2020-10-01)

Editorial: The broader aspects of non-alcoholic fatty liver disease in children
by: Claudia Mandato, et al.
Published: (2022-10-01)

Sequential algorithm to stratify liver fibrosis risk in overweight/obese metabolic dysfunction-associated fatty liver disease
by: Chi-Ho Lee, et al.
Published: (2023-01-01)

Effects of Dietary Nutrients on Fatty Liver Disease Associated With Metabolic Dysfunction (MAFLD): Based on the Intestinal-Hepatic Axis
by: Nan Yao, et al.
Published: (2022-06-01)

Treatments for NAFLD: State of Art
by: Alessandro Mantovani, et al.
Published: (2021-02-01)

A Quantitative Systems Pharmacology Platform Reveals NAFLD Pathophysiological States and Targeting Strategies
by: Daniel E. Lefever, et al.
Published: (2022-06-01)

Prevalence and risk factors of metabolic associated fatty liver disease in the contemporary South China population
by: Jiahua Fan, et al.
Published: (2021-09-01)

Plasma Calprotectin Levels Associate with Suspected Metabolic-Associated Fatty Liver Disease and All-Cause Mortality in the General Population
by: Arno R. Bourgonje, et al.
Published: (2022-12-01)

Non-alcoholic fatty liver disease associated with greater herpes zoster risk than alcoholic fatty liver disease
by: Cheng-Wei Yu, et al.
Published: (2023-12-01)

Therapeutics for Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)
by: Kamlesh K. Bhopale, et al.
Published: (2023-10-01)

Circadian Misalignment Rather Than Sleep Duration is Associated with MAFLD: A Population-Based Propensity Score-Matched Study
by: Weng Z, et al.
Published: (2021-01-01)

Metabolic dysfunction-associated fatty liver disease: current therapeutic strategies
by: Khamis Al Hashmi, et al.
Published: (2024-03-01)

Updated upper limits of normal serum alanine aminotrasferase levels for screening metabolic dysfunction-associated fatty liver disease in obese children
by: Yu-Cheng Lin, et al.
Published: (2022-12-01)

The relationship between metabolic dysfunction-associated fatty liver disease and the incidence rate of extrahepatic cancer
by: Suosu Wei, et al.
Published: (2023-02-01)

MAFLD and CKD: An Updated Narrative Review
by: Alessandro Mantovani, et al.
Published: (2022-06-01)

Atherogenic Index of Plasma in Non-Alcoholic Fatty Liver Disease: Systematic Review and Meta-Analysis
by: Abdulrahman Ismaiel, et al.
Published: (2022-08-01)

Performance of Fatty Liver Index in Identifying Non-Alcoholic Fatty Liver Disease in Population Studies. A Meta-Analysis
by: Marco Castellana, et al.
Published: (2021-04-01)

Metabolic-associated fatty liver disease: a selective review of pathogenesis, diagnostic approaches, and therapeutic strategies
by: Mohammad Habibullah, et al.
Published: (2024-01-01)

Molecular Advances in MAFLD—A Link between Sphingolipids and Extracellular Matrix in Development and Progression to Fibrosis
by: Adrian Kołakowski, et al.
Published: (2022-09-01)

Comparison of the Diagnostic Performance of Steatosis Indices for Discrimination of CT-Diagnosed Metabolic Dysfunction-Associated Fatty Liver Disease
by: A. Lum Han, et al.
Published: (2022-07-01)

High prevalence of non-alcoholic fatty liver disease in patients with a first episode of acute ischemic stroke. Impact on disability and death
by: Lidia Canillas, et al.
Published: (2022-12-01)

The Intersection of COVID-19 and Metabolic-Associated Fatty Liver Disease: An Overview of the Current Evidence
by: Mykhailo Buchynskyi, et al.
Published: (2023-04-01)

Metabolic dysfunction-associated fatty liver disease and the risk of hepatocellular carcinoma
by: Byeong Geun Song, et al.
Published: (2023-09-01)

Impact of MAFLD on HBV-Related Stage 0/A Hepatocellular Carcinoma after Curative Resection
by: Yen-Po Lin, et al.
Published: (2021-07-01)

Association of Lipid Profile and Liver Parameters with Different Grades of Non-alcoholic Fatty Liver Disease
by: Drutpal Baghel, et al.
Published: (2023-03-01)

Effects of PCSK9 inhibitors on metabolic-associated fatty liver disease: a short review
by: Ewelina Jakielska, et al.
Published: (2023-03-01)

Circulating chemerin levels in metabolic-associated fatty liver disease: a systematic review and meta-analysis
by: Qian Ren, et al.
Published: (2022-03-01)

Changes in indicators of fibrosis in patients with alcoholic liver cirrhosis associated with non-alcoholic fatty liver disease depending on the stage of cirrhosis
by: N. R. Matkovska, et al.
Published: (2020-06-01)

Effects of various interventions on non-alcoholic fatty liver disease (NAFLD): A systematic review and network meta-analysis
by: Xinchen Wang, et al.
Published: (2023-03-01)

Adding to the confusion in more than just the name
by: Jacob George
Published: (2023-10-01)

Characteristics of intestinal bacteria with fatty liver diseases and cirrhosis
by: Guohong-Liu, et al.
Published: (2019-11-01)

Varied Relationship of Lipid and Lipoprotein Profiles to Liver Fat Content in Phenotypes of Metabolic Associated Fatty Liver Disease
by: Tingfeng Wu, et al.
Published: (2021-11-01)